Taiji Wang

Education

M.P.H., maternal and child health, University of California, Berkeley; B.S., neuroscience, McGill University

Summary of Experience

Ms. Wang specializes in health care market access strategy and economic modeling across a range of therapeutic areas, including neurodegenerative diseases, oncology, and select rare diseases. Her market access expertise has involved value proposition and evidence strategy generation to support new product launches and label expansions, including the development of formulary dossiers (including Academy of Managed Care Pharmacy dossiers and global value dossiers) and related scientific communication tools. Ms. Wang’s economic modeling experience includes cost-effectiveness analyses and budget impact models to support health technology assessments (HTAs) and regulatory submissions. Her work has been used to inform regulatory and reimbursement decisions in US and global markets and published in peer-reviewed journals. Prior to joining Analysis Group, Ms. Wang applied empirical tools to address scientific, ethical, and policy challenges in the development and translation of health technologies at the Biomedical Ethics Unit of McGill University.